PranaX Corporation, a biotechnology company specializing in regenerative biologics, has successfully closed an oversubscribed $17 million Series A funding round. The investment was led by a consortium of family offices, trusts, and individual investors with extensive expertise in biotechnology, healthcare innovation, and regenerative medicine.
Health Technology Insights: Interwell Health Appoints Dr. Carney Taylor as Chief Medical Officer
This funding comes at a time when exosome-based therapies are gaining attention as a promising area in regenerative medicine. As both consumers and healthcare providers seek biologically informed solutions to support healthy aging and overall wellness, exosomes are increasingly seen as a cornerstone for next-generation regenerative strategies. PranaX continues to advance the field with innovative exosome technologies aimed at helping individuals maintain or restore their quality of life. The company envisions a future where the challenges of aging and degeneration no longer limit the pursuit of a long and fulfilling life.
Health Technology Insights: MS Pharma Group Signs Exclusive Biosimilars Deal with Hetero
“PranaX was created with the belief that exosomes can transform how we approach aging and wellness,” said Steven J. Greco, PhD, Founder and Chief Operating Officer of PranaX. “Our platform combines rigorous scientific research with practical applications that can make a real difference. This financing confirms our mission and unique approach, giving us the resources to scale responsibly while maintaining the highest standards of scientific integrity.”
Funds from the Series A round will support PranaX’s research and development programs, expand its scientific and operational infrastructure, foster strategic partnerships, and accelerate product development and commercialization. As the company moves into its next growth phase, it remains committed to advancing regenerative biologics through responsible innovation, strict scientific rigor, and a focus on improving the quality of life for patients.
Health Technology Insights: Lunai Bioworks Expands AI Program for Alcohol Use Disorder Drugs
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
